久久综合日本久久综合,亚洲成AV人片在线观看天堂无码,国产在线视频不卡一区二区,久久久久看免费高清特色大片

武漢佰樂博生物技術(shù)有限公司
   
     
聯(lián)系熱線
  • 聯(lián)系人:方經(jīng)理
  • 電 話:027-65279366
  • 郵箱:products@biolabreagent.com
  • 地 址:武漢市東湖新技術(shù)開發(fā)區(qū)神墩四路666號C棟

武漢佰樂博代理:Research Grade Sabatolimab

發(fā)表時間:2023-06-30

武漢佰樂博代理:Research Grade Sabatolimab  

貨號DHJ28402

產(chǎn)品鏈接:http://www.atagenix.com/product_detail-75240.html

產(chǎn)品購買聯(lián)系方式:027-65279366

產(chǎn)品介紹:Sabatolimab (MBG453)是一種高親和力的人源化IgG4 (S228P)抗體,靶向TIM-3,一種調(diào)節(jié)適應(yīng)性和先天免疫反應(yīng)的抑制性受體。Sabatolimab是一種潛在的免疫抑制活性分子,可以靶向免疫細(xì)胞和骨髓細(xì)胞上的TIM-3。

通用名:Sabatolimab

純度:>95% by SDS-PAGE.

濃度:1mg/ml

Formulationicon:0.01M PBS, pH 7.4.

內(nèi)毒素:Please contact with the lab for this information.

別名:MBG-453

靶點(diǎn);物種:Human CD366/HAVCR2/TIM-3

種類:Humanized

受體鑒定:IgG4-kappa

CAS: 2252262-24-9

存儲條件:Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

參考文獻(xiàn):

Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. PMID: 33883177

Advances in myelodysplastic syndrome. PMID: 34474438

Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor. PMID: 36196369

Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes. PMID: 35883692

Updates on the Management of Acute Myeloid Leukemia. PMID: 36230677

Sabatolimab (MBG453) model-informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors. PMID: 37186155

New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes. PMID: 35886899

STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. PMID: 37083373

TIM-3: a tumor-associated antigen beyond checkpoint inhibition? PMID: 36406467

Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor. PMID: 36819977

[Management of AML in the elderly]. PMID: 36870810

New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors. PMID: 35218498

EXABS-120-MDS Treatment of Higher Risk MDS. PMID: 36163758

EXABS-140-MDS Immune Therapy Approaches in MDS. PMID: 36164227

Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon? PMID: 33762100

Advances in myelodysplastic syndromes: promising novel agents and combination strategies. PMID: 36620919

Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: pitfalls and recommendations. PMID: 36215988

Biological therapy in elderly patients with acute myeloid leukemia. PMID: 36715330

Modulation of the Gal-9/TIM-3 Immune Checkpoint with α-Lactose. Does Anomery of Lactose Matter? PMID: 34944985

聯(lián)系方式
手機(jī):18162686757
微信掃一掃
岑巩县| 平凉市| 鄂伦春自治旗| 南岸区| 吴川市| 新密市| 称多县| 灵丘县| 辽中县| 丽江市| 雅安市| 广汉市| 蓝山县| 武城县| 义乌市| 广南县| 云梦县| 卓资县| 三台县| 蓬溪县| 沾益县| 化德县| 唐海县| 兴业县| 汉中市| 内丘县| 晋城| 延庆县| 衢州市| 星座| 辽中县| 乃东县| 科技| 花莲市| 宁河县| 井冈山市| 永城市| 水城县| 延津县| 罗平县| 咸阳市|